Citalopram combined with WAY 100635 inhibits ejaculation and ejaculation-related Fos immunoreactivity

Trynke R. De Jong, Tommy Pattij, Jan G. Veening, P. Jos W.C. Dederen, Marcel D. Waldinger, Alexander R. Cools, Berend Olivier

Research output: Contribution to journalArticleAcademicpeer-review

66 Citations (Scopus)


The role of 5-HT (5-hydroxytryptamine, 5-HT)1A receptor activation in the sexual side-effects, in particular delayed ejaculation, of selective serotonin reuptake inhibitors (SSRIs) was studied. Male Wistar rats were treated for 15 days with vehicle, the SSRI citalopram (10 mg/kg/day p.o.), the 5-HT1A receptor antagonist N-[2-[4-(2-methoxyphenyl)-1- piperazinyl] ethyl]-N-(2-pyridinyl) cyclohexane carboxamide 3HCL (WAY 100635, 0.1 mg/kg/ day s.c.), or both drugs combined. Sexual behavior was assessed weekly. One h after the last sexual behavior test, rat brains were processed for Fos-immunohistochemistry. Acute and chronic citalopram mildly inhibited ejaculation, which was strongly augmented by co-administration of WAY 100635. WAY 100635 alone did not alter sexual behavior. Brain sites associated with ejaculation showed reduced Fos-immunoreactivity in rats treated with both citalopram and WAY 100635. Citalopram reduced Fos-immunoreactivity in the arcuate hypothalamic nucleus, an area that might link serotonergic neurotransmission to ejaculation.

Original languageEnglish
Pages (from-to)49-59
Number of pages11
JournalEuropean journal of pharmacology
Issue number1
Publication statusPublished - 10 Feb 2005


  • 5-HT
  • Antidepressant
  • Ejaculation
  • Selective serotonin reuptake inhibitor
  • c-fos

Cite this